



# LBDA

LEWY BODY DEMENTIA ASSOCIATION

---

RESEARCH CENTERS OF EXCELLENCE

## Publication List July 2020 – July 2021

### LBDA-supported research and activities

Goldman JG, Forsberg LK, Boeve BF, Armstrong MJ, Irwin DJ, Ferman TJ, Galasko D, Galvin JE, Kaufer D, Leverenz J, Lippa CF, Marder K, Abler V, Biglan K, Irizarry M, Keller B, Munsie L, Nakagawa M, Taylor A, Graham T. **Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.** *Alzheimers Res Ther.* 2020 Oct 29;12(1):137. doi: 10.1186/s13195-020-00703-5. PMID: 33121510

Goldman JG, Boeve BF, Armstrong MJ, Galasko DR, Galvin JE, Irwin DJ, Leverenz JB, Marder K, Abler V, Biglan K, Irizarry MC, Keller B, Lai R, Munsie L, Belleville M, Chaney O, Richard I, Taylor A, Graham T. **Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting.** *Alzheimers Res Ther.* 2021 Jul 8;13(1):124. doi: 10.1186/s13195-021-00868-7. PMID: 34238345

Armstrong MJ, Irwin DJ, Leverenz JB, Gamez N, Taylor A, Galvin JE. **Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts.** *Alzheimer Dis Assoc Disord.* 2021 Jan-Mar 01;35(1):55-61. doi: 10.1097/WAD.0000000000000414. PMID: 33009039; PMCID: PMC7904569.

Armstrong MJ, Sullivan JL, Amodeo K, Lunde A, Tsuang DW, Reger MA, Conwell Y, Ritter A, Bang J, Onyike CU, Mari Z, Corsentino P, Taylor A. **Suicide and Lewy body dementia: Report of a Lewy Body Dementia Association working group.** *Int J Geriatr Psychiatry.* 2021 Mar;36(3):373-382.

### Additional research in dementia with Lewy bodies, Parkinson's disease with dementia, and Lewy body disease

Ferman TJ, Aoki N, Boeve BF, Aakre JA, Kantarci K, Graff-Radford J, Parisi JE, Van Gerpen JA, Graff-Radford NR, Uitti RJ, Pedraza O, Murray ME, Wszolek ZK, Reichard

RR, Fields JA, Ross OA, Knopman DS, Petersen RC, Dickson DW. Subtypes of dementia with Lewy bodies are associated with  $\alpha$ -synuclein and tau distribution. *Neurology*. 2020;95(2):e155-e65. Jul 14;95(2):e155-e165. doi: 10.1212/WNL.00000000000009763. Epub 2020 Jun 19. PMID: 32561678.

Ferreira D, Przybelski SA, Lesnick TG, Lemstra AW, Londos E, Blanc F, Nedelska Z, Schwarz CG, Graff-Radford J, Senjem ML, Fields JA, Knopman DS, Savica R, Ferman TJ, Graff-Radford NR, Lowe VJ, Jack CR Jr, Petersen RC, Mollenhauer B, Garcia-Ptacek S, Abdelnour C, Hort J, Bonanni L, Oppedal K, Kramberger MG, Boeve BF, Aarsland D, Westman E, Kantarci K. Amyloid- $\beta$  and tau biomarkers and clinical phenotype in dementia with Lewy bodies. *Neurology*. 2020 Sep 28;10.1212/WNL.0000000000010943. doi: 10.1212/WNL.0000000000010943. PMID: 32989106

Strickland SL, Morel H, Prusinski C, Allen M, Patel TA, Carrasquillo MM, Conway OJ, Lincoln SJ, Reddy JS, Nguyen T, Malphrus KG, Soto AI, Walton RL, Crook JE, Murray ME, Boeve BF, Petersen RC, Lucas JA, Ferman TJ, Uitti RJ, Wszolek ZK, Ross OA, Graff-Radford NR, Dickson DW, Ertekin-Taner N. Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. *Acta Neuropathol Commun*. 2020 Oct 22;8(1):172. doi: 10.1186/s40478-020-01050-0. PMID: 33092647

Chen Q, Lowe VJ, Boeve BF, Przybelski SA, Miyagawa T, Senjem ML, Jack CR Jr, Lesnick TG, Kremers WK, Fields JA, Min HK, Schwarz CG, Gunter JL, Graff-Radford J, Savica R, Knopman DS, Jones D, Ferman TJ, Graff-Radford NR, Petersen RC, Kantarci K.  $\beta$ -Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. *Neurology*. 2021 Jan 6;10.1212/WNL.0000000000011454. doi: 10.1212/WNL.0000000000011454. PMID: 33408148

Miyagawa T, Przybelski SA, Maltais D, Min HK, Jordan L, Lesnick TG, Chen Q, Graff-Radford J, Jones D, Savica R, Knopman D, Petersen R, Kremers WK, Forsberg LK, Fields JA, Ferman TJ, Allen L, Parisi J, Reichard RR, Murray M, Dickson D, Boeve BF, Kantarci K, Lowe VJ. The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. *Neurobiol Aging*. 2021 Mar;99:11-18. doi: 10.1016/j.neurobiolaging.2020.12.009. Epub 2020 Dec 15. PMID: 33422890

Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, Walton RL, Ahmed S, Viollet C, Ding J, Makarious MB, Diez-Fairen M, Portley MK, Shah Z, Abramzon Y, Hernandez DG, Blauwendraat C, Stone DJ, Eicher J, Parkkinen L, Ansorge O, Clark L, Honig LS, Marder K, Lemstra A, St George-Hyslop P, Londos E, Morgan K, Lashley T, Warner TT, Jaunmuktane Z, Galasko D, Santana I, Tienari PJ, Myllykangas L, Oinas M, Cairns NJ, Morris JC, Halliday GM, Van Deerlin VM, Trojanowski JQ, Grassano M, Calvo A, Mora G, Canosa A, Floris G, Bohannon RC, Brett F, Gan-Or Z, Geiger JT, Moore A, May P, Krüger R, Goldstein DS, Lopez G,

Tayebi N, Sidransky E; American Genome Center, Norcliffe-Kaufmann L, Palma JA, Kaufmann H, Shakkottai VG, Perkins M, Newell KL, Gasser T, Schulte C, Landi F, Salvi E, Cusi D, Masliah E, Kim RC, Caraway CA, Monuki ES, Brunetti M, Dawson TM, Rosenthal LS, Albert MS, Pletnikova O, Troncoso JC, Flanagan ME, Mao Q, Bigio EH, Rodríguez-Rodríguez E, Infante J, Lage C, González-Aramburu I, Sanchez-Juan P, Ghetti B, Keith J, Black SE, Masellis M, Rogaeva E, Duyckaerts C, Brice A, Lesage S, Xiromerisiou G, Barrett MJ, Tilley BS, Gentleman S, Logroscino G, Serrano GE, Beach TG, McKeith IG, Thomas AJ, Attems J, Morris CM, Palmer L, Love S, Troakes C, Al-Sarraj S, Hodges AK, Aarsland D, Klein G, Kaiser SM, Woltjer R, Pastor P, Bekris LM, Leverenz JB, Besser LM, Kuzma A, Renton AE, Goate A, Bennett DA, Scherzer CR, Morris HR, Ferrari R, Albani D, Pickering-Brown S, Faber K, Kukull WA, Morenas-Rodríguez E, Lleó A, Fortea J, Alcolea D, Clarimon J, Nalls MA, Ferrucci L, Resnick SM, Tanaka T, Foroud TM, Graff-Radford NR, Wszolek ZK, Ferman T, Boeve BF, Hardy JA, Topol EJ, Torkamani A, Singleton AB, Ryten M, Dickson DW, Chiò A, Ross OA, Gibbs JR, Dalgard CL, Traynor BJ, Scholz SW. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nat Genet.* 2021 Feb 15. doi: 10.1038/s41588-021-00785-3. PMID: 33589841

Chen Q, Boeve BF, Forghanian-Arani A, Senjem ML, Jack CR Jr, Przybelski SA, Lesnick TG, Kremers WK, Fields JA, Schwarz CG, Gunter JL, Trzasko JD, Graff-Radford J, Savica R, Knopman DS, Dickson DW, Ferman TJ, Graff-Radford N, Petersen RC, Kantarci K. MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. *J Neuroimaging.* 2021 May 25. doi: 10.1111/jon.12878. PMID: 34033185

Armstrong MJ, Paulson HL, Maixner SM, Fields JA, Lunde AM, Boeve BF, Manning C, Galvin JE, Taylor AS, Li Z. Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study. *BMJ Open.* 2021 May 26;11(5):e047554. doi: 10.1136/bmjopen-2020-047554. PMID: 34039578

Schumacher J, Gunter JL, Przybelski SA, Jones DT, Graff-Radford J, Savica R, Schwarz CG, Senjem ML, Jack CR, Lowe VJ, Knopman DS, Fields JA, Kremers WK, Petersen RC, Graff-Radford NR, Ferman TJ, Boeve BF, Thomas AJ, Taylor JP, Kantarci K. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. *Brain.* 2021 Jun 11:awab218. doi: 10.1093/brain/awab218. PMID: 34114602

Ferreira D, Nedelska Z, Graff-Radford J, Przybelski SA, Lesnick TG, Schwarz CG, Botha H, Senjem ML, Fields JA, Knopman DS, Savica R, Ferman TJ, Graff-Radford NR, Lowe VJ, Jack CR, Petersen RC, Lemstra AW, van de Beek M, Barkhof F, Blanc F, Loureiro de Sousa P, Philippi N, Cretin B, Demuynck C, Hort J, Oppedal K, Boeve BF, Aarsland D, Westman E, Kantarci K. Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. *Neurobiol Aging.* 2021 May 14;105:252-261. doi: 10.1016/j.neurobiolaging.2021.04.029. PMID: 34130107

Lang FM, Kwon DY, Aarsland D, Boeve B, Tousi B, Harnett M, Mo Y, Noel Sabbagh M. An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). *Alzheimers Dement (N Y)*. 2021 Jun 20;7(1):e12171. doi: 10.1002/trc2.12171. PMID: 34189249

Kantarci K, Boeve BF, Przybelski SA, Lesnick TG, Chen Q, Fields J, Schwarz CG, Senjem ML, Gunte JL, Jack CR, Min P, Jain M, Migayawa T, Savica R, Graff-Radford J, Botha H, Jones DT, Knopman DS, Graff-Radford N, Ferman TJ, Petersen RC, Lowe VJ. FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. *Neuroimage Clin*. 2021 Jul 4;31:102754. doi: 10.1016/j.nicl.2021.102754. PMID: 34252877

Buciuc M, Whitwell JL, Kasanuki K, Graff-Radford J, Machulda MM, Duffy JR, Strand EA, Lowe VJ, Graff-Radford NR, Rush BK, Franczak MB, Flanagan ME, Baker MC, Rademakers R, Ross OA, Ghetti BF, Parisi JE, Raghunathan, Reichard RR, Bigio EH, Dickson DW, Josephs KA. Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. *Ann Neurol*. 2021 Mar;89(3):520-533. doi: 10.1002/ana.25979. Epub 2020 Dec 17.

Gupta HV, Beach TG, Mehta SH, Shill HA, Driver-Dunckley E, Sabbagh MN, Belden CM, Liebsack C, Dugger BN, Serrano GE, Sue LI, Siderowf A, Pontecorvo MJ, Mintun MA, Joshi AD, Adler CH. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. *J Alzheimer's Dis*. 2021 Mar 9. doi:10.3233/JAD-200323. PMID: 33720879.

Beach TG, Adler CH, Sue LI, Shill HA, Driver-Dunckley E, Mehta SH, Intorcchia AJ, Glass MJ, Walker JE, Arce R, Nelson CM and Serrano GE. Vagus Nerve and Stomach Synucleinopathy in Parkinson's Disease, Incidental Lewy Body Disease and Normal Elderly Subjects: Evidence Against the "Body-First" Hypothesis. *J Parkinson Dis*, 2021 Jun 14. doi:10.3233/JPD-212733.

Pillai JA, Bena J, Bonner-Jackson A, Leverenz JB. Impact of APOE  $\epsilon$ 4 genotype on initial cognitive symptoms differs for Alzheimer's and Lewy body neuropathology. *Alzheimers Res Ther*. 2021 Jan 23;13(1):31. doi:10.1186/s13195-021-00771-1. PMID: 33485373; PMCID: PMC7825215.

Tousi B, Leverenz JB. The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data. *Drug Des Devel Ther*. 2021 May 3;15:1811-1817. doi: 10.2147/DDDT.S240865. PMID: 33976533; PMCID: PMC8106402.

Levy O, Hickman RA, Marder KS *Lewy Body Disorders in Merritt's Neurology*. 2021. eds ED Louis, SA Mayer, JM Noble. 14th Ed. Chpt. 53. Wolters Kluwer: Phil

Kegelmeyer DA, Kostyk SK, Fritz NE, Scharre DW, Young GS, Tan Y, Schubert R, Reilmann R, Kloos AD. Immediate effects of treadmill walking in individuals with Lewy body dementia and Huntington's disease. *Gait Posture* 2021 May;86:186-191

Pilotto A, Romagnolo A, Scalvini A, Masellis M, Shimo Y, Bonanni L, Camicioli R, Wang LL, Dwivedi AK, Longardner K, Rodriguez-Porcel F, DiFrancesco M, Vizcarra JA, Montanaro E, Maule S, Lupini A, Ojeda-Lopez C, Black SE, Pizzi SD, Gee M, Tanaka R, Yamashiro K, Hatano T, Borroni B, Gasparotti R, Rizzetti MC, Hattori N, Lopiano L, Litvan I, Espay AJ, Padovani A, Merola A. Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. *Neurology* 2021 Jun 7:10.1212/WNL.0000000000012342. doi: 10.1212/WNL.0000000000012342. PMID: 34099524.

Phongpreecha T, Cholerton B, Mata IF, Zabetian CP, Poston KL, Aghaeepour N, Tian L, Quinn JF, Chung KA, Hiller AL, Hu SC, Edwards KL, Montine TJ. Multivariate prediction of dementia in Parkinson's disease. *NPJ Parkinsons Dis.* 2020 Aug 25;6:20.

Fleisher JE, et al. Disease severity and quality of life in homebound people with advanced Parkinson disease: A pilot study. *Neurol Clin Pract.* 2020 Aug;10(4):277-286. doi: 10.1212/CPJ.0000000000000716. PMID: 32983607; PMCID: PMC7508339.

Espay AJ, Marsili L, Mahajan A et al. Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. *Ann Neurol.* 2020 Oct 5. doi: 10.1002/ana.25923. PMID: 33016374.

Pezzoli S, Sánchez-Valle R, Solanes A, Kempton M, Bandmann O, Shin JI, Cagnin A, Goldman J, Merkitch D, Firbank M, Taylor JP, Pagonabarraga J, Kulisevsky J, Blanc F, Venneri A, Radua J. Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: voxel-based morphometry and neuropsychological meta-analysis. *Neuroscience and Biobehavioral Reviews.* 2021 Sep;128:367-382. doi: 10.1016/j.neubiorev.2021.06.030. Epub 2021 Jun 22. PMID: 34171324.

Ryman SG, Yutsis M, Tian L, Henderson VW, Montine TJ, Salmon DP, Galasko D, Poston KL. Cognition at each stage of Lewy body disease with co-occurring Alzheimer's disease pathology. *Journal of Alzheimer's Disease* 2021;80(3):1243-1256

Zarifkar P, Kim J, La C, Zhang K, YorkWilliams S, Levine TF, Tian L, Borghammer P, Poston KL. Cognitive impairment in Parkinson's Disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid A $\beta$ . *Parkinsonism and Related Disorders* 2021 Jan 12;83:71-78.

Kurasz, AM, Smith GE, McFarland MG, Armstrong MJ. Ethnoracial Differences in Lewy Body Diseases with Cognitive Impairment. *J Alzheimers Dis.* 2020;77(1):165-174.

Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. *JAMA* 2020;323(6):548-560. doi: 10.1001/jama.2019.22360. (includes information about PDD)

Longardner K, Dickson DW, Litvan I. Orthostatic hypotension preceding dementia with Lewy bodies by over 15 years: a clinicopathologic case report. *Clin Auton Res*. 2020 Dec;30(6):575-577. doi: 10.1007/s10286-020-00730-0. Epub 2020 Sep 16. PMID: 32939679

Pilotto A, Romagnolo A, Scalvini A, Masellis M, Shimo Y, Bonanni L, Camicioli R, Wang LL, Dwivedi AK, Longardner K, Rodriguez-Porcel F, DiFrancesco M, Vizcarra JA, Montanaro E, Maule S, Lupini A, Ojeda-Lopez C, Black SE, Pizzi SD, Gee M, Tanaka R, Yamashiro K, Hatano T, Borroni B, Gasparotti R, Rizzetti MC, Hattori N, Lopiano L, Litvan I, Espay AJ, Padovani A, Merola A. Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. *Neurology*. 2021 Jun 7;10.1212/WNL.0000000000012342. doi: 10.1212/WNL.0000000000012342. PMID: 34099524

Bayram E, Coughlin DG, Banks SJ, Litvan I. Sex differences for phenotype in pathologically defined dementia with Lewy bodies. *J Neurol Neurosurg Psychiatry*. 2021 Jul;92(7):745-750. doi: 10.1136/jnnp-2020-325668. Epub 2021 Feb 9. PMID: 33563809

Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, Beck JC, Lyles KW. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. *NPJ Parkinsons Dis*. 2021 Mar 1;7(1):16. doi: 10.1038/s41531-021-00162-1. PMID: 33649343; PMCID: PMC7921548.

Park J, Galvin JE. Pre-loss grief in caregivers of older adults with dementia with Lewy bodies. *J Alzheimer Dis*, 2021 Jul 2. doi: 10.3233/JAD-210616.

Galvin JE, Chrisphonte S, Cohen I, Greenfield K, Kleiman MJ, Moore C, Riccio ML, Rosenfeld A, Shkolnik N, Walker M, Change LC, Tolea MI. Characterization of Dementia with Lewy Bodies (DLB) and Mild Cognitive Impairment Using the Lewy Body Dementia Module (LBD-MOD). *Alzheimers Dementia* 2021 Apr 1 doi:10.1002/alz.12334

Rigby T, Johnson DK, Taylor A, Galvin JE. Comparison of the Caregiving Experience of Grief, Burden, and Quality of Life in Dementia with Lewy Bodies, Alzheimer's Disease, and Parkinson's Disease Dementia. *J Alzheimers Dis* 80:421-432;2021.

Armstrong MJ, Alliance S, Corsentino P, Maixner SM, Paulson HL, Taylor A. Caregiver-Reported Barriers to Quality End-of-Life Care in Dementia With Lewy Bodies: A Qualitative Analysis. *Am J Hosp Palliat Care*. 2020 Sep;37(9):728-737. doi: 10.1177/1049909119897241. PMID: 31902223

Irwin D, Saint-Hilaire M. In Vivo Detection of Underlying Synucleinopathies: Are We There Yet? *Neurology*. 2021 May 18;96(20):925-926. doi: 10.1212/WNL.0000000000011929. PMID: 33858996

Coughlin DG, Grossman M, Trojanowski JQ, Irwin DJ. Hippocampal subfield pathologic Burden in Lewy body diseases versus Alzheimer's disease. *Neuropathol Appl Neurobiol*. 2021 Aug;47(5):707-708. doi: 10.1111/nan.12698. PMID: 33492664

Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, Spindler M, Deik A, Chen-Plotkin A, Siderowf A, Dahodwala N, Weintraub D, Shaw LM, Trojanowski JQ, Vaishnavi SN, Wolk DA, Mechanic-Hamilton D, Morley JF, Duda JE, Grossman M, Cousins KAQ. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. *Neurology*. 2021 Apr 6;96(14):e1855-e1864. doi: 10.1212/WNL.0000000000011699. Epub 2021 Feb 16. PMID: 33593865

Gupta HV, Beach TG, Mehta SH, Shill HA, Driver-Dunckley E, Sabbagh MN, Belden CM, Liebsack C, Dugger BN, Serrano GE, Sue LI, Siderowf A, Pontecorvo MJ, Mintun MA, Joshi AD, Adler CH. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. *J Alzheimers Dis*. 2021;80(4):1603-1612. doi: 10.3233/JAD-200323. PMID: 33720879

Koyama AK, Irwin DJ. Alzheimer disease biomarker profiles in dementia with Lewy bodies: Does A plus T spell D-L-B? *Neurology*. 2020 Dec 15;95(24):1076-1077. doi: 10.1212/WNL.0000000000010958. Epub 2020 Sep 28. PMID: 32989112

Coughlin DG, Phillips JS, Roll E, Peterson C, Lobrovich R, Rascovsky K, Ungrady M, Wolk DA, Das S, Weintraub D, Lee EB, Trojanowski JQ, Shaw LM, Vaishnavi S, Siderowf A, Nasrallah IM, Irwin DJ, McMillan CT. Multimodal in vivo and postmortem assessments of tau in Lewy body disorders. *Alzheimer's Disease Neuroimaging Initiative*. *Neurobiol Aging*. 2020 Dec;96:137-147. doi: 10.1016/j.neurobiolaging.2020.08.003. Epub 2020 Aug 21. PMID: 33002767

Spotorno N, Coughlin DG, Olm CA, Wolk D, Vaishnavi SN, Shaw LM, Dahodwala N, Morley JF, Duda JE, Deik AF, Spindler MA, Chen-Plotkin A, Lee EB, Trojanowski JQ, McMillan CT, Weintraub D, Grossman M, Irwin DJ. Tau pathology associates with in vivo cortical thinning in Lewy body disorders. *Ann Clin Transl Neurol*. 2020 Dec;7(12):2342-2355. doi: 10.1002/acn3.51183. Epub 2020 Oct 27. PMID: 33108692

Cummings J, Pinto LC, Cruz M, Fischer CE, Gerritsen DL, Grossberg GT, Hwang TJ, Ismail Z, Jeste DV, Koopmans R, Lanctot KL, Mateos R, Peschin S, Sampaio C, Tsuang D, Wang H, Zhong K, Bain LJ, Sano M. Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. *Am J Geriatr Psychiatry*. 2020 Dec;28(12):1256-1269. PMID: 32958332

**Additional clinical research related to other LBD-related neurodegenerative disorders (e.g., Parkinson's disease, REM sleep behavior disorder, dementia, etc.) (n=91)**

Mufti K, Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Högl B, Stefani A, Holzknecht E, Šonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Döring F, Cochen De Cock V, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Postuma RB, Rouleau GA, Gan-Or Z. Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder. *Mov Disord.* 2020 Oct 1. doi: 10.1002/mds.28318. PMID: 33001463

Stang CD, Mullan AF, Hajeb M, Camerucci E, Turcano P, Martin P, Mielke MM, Josephs KA, Bower JH, St Louis EK, Boeve BF, Savica R. Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt Alpha-Synucleinopathies. *Ann Neurol.* 2020 Nov 6. doi: 10.1002/ana.25952. PMID: 33155696

Arnaldi D, Chincarini A, Hu MT, Sonka K, Boeve B, Miyamoto T, Puligheddu M, De Cock VC, Terzaghi M, Plazzi G, Tachibana N, Morbelli S, Rolinski M, Dusek P, Lowe V, Miyamoto M, Figorilli M, de Verbizier D, Bossert I, Antelmi E, Meli R, Barber TR, Trnka J, Miyagawa T, Serra A, Pizza F, Bauckneht M, Bradley KM, Zogala D, McGowan DR, Jordan L, Manni R, Nobili F. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. *Brain.* 2020 Dec 22:awaa365. doi: 10.1093/brain/awaa365. PMID: 33348363

Mufti K, Yu E, Rudakou U, Krohn L, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Bernardini A, Högl B, Stefani A, Holzknecht E, Sonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Döring F, De Cock VC, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Trempe JF, Rouleau GA, Postuma RB, Gan-Or Z. Novel Associations of BST1 and LAMP3 with Rapid Eye Movement Sleep Behavior Disorder. *Neurology.* 2021 Jan 4:10.1212/WNL.0000000000011464. doi: 10.1212/WNL.0000000000011464. Online ahead of print. PMID: 33397775

Gossard TR, McCarter SJ, Gorres E, Feemster JC, Timm PC, Teigen LN, Ralston CL, Westerland SM, Conway JP, Jagielski JT, Olson CD, Edgar LJ, Veum EL, Savica R, Boeve BF, Silber MH, St Louis EK. Quantitative REM Sleep without Atonia in Parkinson's Disease and Essential Tremor. *Mov Disord Clin Pract.* 2020 Nov 26;8(1):37-43. doi: 10.1002/mdc3.13112. eCollection 2021 Jan. PMID: 33426157

Teigen LN, Sharp RR, Hirsch JR, Campbell E, Timm PC, Sandness DJ, Feemster JC, Gossard TR, Faber SM, Steele TA, Rivera S, Junna MR, Lipford MC, Tippmann-Peikert M, Kotagal S, Ju YE, Howell M, Schenck CH, Videnovic A, Jennum P, Högl B, Stefani



A, Arnulf I, Heidebreder A, Lewis S, McCarter SJ, Boeve BF, Silber MH, St Louis EK. Specialist approaches to prognostic counseling in isolated REM sleep behavior disorder. *Sleep Med.* 2020 Dec 24;79:107-112.

Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Mehta SH, Atri A, Caviness JN, Serrano GE, Shprecher D, Sue LI, and Belden CM. Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: Updated Clinicopathologic Study. *Neurology Clin Practice*, in press. Damron L, Litvan I, Bayram E, Siddiqi B, Shill H. Hispanic perspectives on Parkinson's disease care and research participation. *J Alzheimers Dis.* 2021;81(2):809-819. doi: 10.3233/JAD-210231. PMID: 33843687.DOI: 10.3233/JAD-210231

Pillai JA, Khrestian M, Bena J, Leverenz JB, Bekris LM. Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes. *Front Aging Neurosci.* 2021 Jun 29;13:676744. doi: 10.3389/fnagi.2021.676744. PMID: 34276339; PMCID: PMC8279003.

Pillai JA, Bebek G, Khrestian M, Bena J, Bergmann CC, Bush WS, Leverenz JB, Bekris LM. *<i>TNFRSF1B</i>* Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease. *Front Aging Neurosci.* 2021 Feb 25;13:638922. doi: 10.3389/fnagi.2021.638922. PMID: 33716716; PMCID: PMC7947258.

Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, Kinney JW, Tousi B, Leverenz JB, Fillit H, Zhong K, Feldman HH, Cummings J. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. *Alzheimers Dement (N Y).* 2021 Feb 14;7(1):e12106. doi: 10.1002/trc2.12106. PMID: 33614888; PMCID: PMC7882538.

Kunkle BW et al, Leverenz JB et al, Kukull WA. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurol.* 2021 Jan 1;78(1):102-113. doi:10.1001/jamaneurol.2020.3536. PMID: 33074286; PMCID: PMC7573798.

Pillai JA, Bena J, Bebek G, Bekris LM, Bonner-Jackson A, Kou L, Pai A, Sørensen L, Neilsen M, Rao SM, Chance M, Lamb BT, Leverenz JB; Alzheimer's Disease Neuroimaging Initiative. Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease. *Ann Clin Transl Neurol.* 2020 Jul;7(7):1225-1239. doi: 10.1002/acn3.51109. Epub 2020 Jul 7. PMID: 32634865; PMCID: PMC7359114.

Alcalay RN, Wolf P, Chiang MSR, et al.. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. *Ann Clin Transl Neurol* 7(10):1816-1830. Epub 2020 Sep 5. PMID: 32888397.

Avisar H, Guardia-Laguarta C, Area-Gomez E, et al.. Lipidomics Prediction of Parkinson's Disease Severity: A Machine-Learning Analysis. *J Parkinsons Dis.* 2021 Mar 29. doi: 10.3233/JPD-202476. PMID: 33814463.

Bloem BR, Trenkwalder C, Sanchez-Ferro A, et al.. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? *J Parkinsons Dis.* 2021; 11(1):3-8. PMID: 33523021.

Cook L, Schulze J, Kopil C, et al.. Genetic Testing for Parkinson Disease: Are We Ready? *Neurol Clin Pract.* 2021 Feb;11(1):69-77. PMID: 33968475.

Cook L, Schulze J, Naito A, Alcalay RN. The Role of Genetic Testing for Parkinson's Disease. *Curr Neurol Neurosci Rep* 2021 Mar 8;21(4):17. PMID: 33686495.

Dhanwani R, Pham J, Premal ALR, ... Marder KS, Sulzer D, Sette A, Lindestam Arlehamn CS. T Cell Responses to Neural Autoantigens Are Similar in Alzheimer's Disease Patients and Age-Matched Healthy Controls. *Front Neurosci.* 2020 Aug 27;14:874. Erratum in: *Front Neurosci.* 2021 Jan 13;14:641809. PMID: 32982670.

Dutta S, Hornung S, Kruayatidee A, et al.. alpha-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. *Acta Neuropathol.* 2021 May 15. doi: 10.1007/s00401-021-02324-0. PMID: 33991233.

Fan Y, Nirujogi RS, Garrido A, et al.. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. *Acta Neuropathol.* 2021 Jun 14. doi: 10.1007/s00401-021-02325-z. PMID: 34125248.

Feeney MP, Xu Y, Surface M, et al.. The impact of COVID-19 and social distancing on people with Parkinson's disease: a survey study. *NPJ Parkinsons Dis.* 2021 Jan 21;7(1):10. doi: 10.1038/s41531-020-00153-8. PMID: 33479241.

Galper J, Balwani M, Fahn S, et al.. Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease. *Mov Disord.* 2021 Jun;36(6):1451-1455. Epub 2021 Feb 11. PMID: 33570220.

Goldman J, Xie S, Green D, Naini A, Mansukhani MM, Marder K. Predictive testing for neurodegenerative diseases in the age of next-generation sequencing. *J Genet Couns.* 2020 Oct 8. doi: 10.1002/jgc4.1342. PMID: 33090625.

Honig LS, Salardini A, Kreisl WC, Noble JM. Mild Cognitive Impairment. in *Merritt's Neurology.* 2021. eds. ED Louis, SA Mayer, JM Noble. 14th Ed. Chpt. 50. Wolters Kluwer: Phil.

Honig LS. Dementia. in *On Call Neurology.* 2020. ed. SA Mayer & RS Marshall. 4th Ed. Chpt. 28. pp. 456-473. Elsevier: St. Louis.

Lai D, Alipanahi B, Fontanillas P, et al.. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Ann Neurol* 90(1):76-88. Epub 2021 May 17. PMID: 33938021.

Naito A, Wills AM, Tropea TF, et al.. Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. *NPJ Parkinsons Dis.* 2021 Apr 12;7(1):34. PMID: 33846349.

Ortega RA, Wang C, Raymond D, ... Marder KS, ... Ozelius LJ, Bressman SB, Saunders-Pullman R. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression. *JAMA Netw Open.* 2021 Apr 1;4(4):e215845. PMID: 33881531.

Rudakou U, Yu E, Krohn L, et al.. Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations. *Brain.* 2021 Mar 3;144(2):462-472. doi: 10.1093/brain/awaa401. PMID: 33349842.

San Luciano M, Tanner CM, Meng C, et al.. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. *Mov Disord* 35(10):1755-1764. Epub 2020 Jul 14. PMID: 3266253.

Sosero YL, Yu E, Krohn L, et al.. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. *Neurobiol Aging.* 2021 Jul;103:142.e1-142.e5. Epub 2021 Feb 28. PMID: 33781610.

Virreira Winter S, Karayel O, Strauss MT, et al.. Urinary proteome profiling for stratifying patients with familial Parkinson's disease. *EMBO Mol Med.* 2021 Mar 5;13(3):e13257. Epub 2021 Jan 22. PMID: 33481347.

Walker JM, Richardson TE, Farrell K, ...Honig L, ... Yu L, White CL, Crary JF. Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. *J Neuropathol Exp Neurol* 80(2):102-111. Epub 2021 Jan 20. PMID: 33367843.

Langley J, Hussain S, Huddleston D, Bennett I, and Hu X. Impact of locus coeruleus and its projections on memory and aging. *Brain Connectivity.* (2021) Jun 17. PMID: 34139886. doi:10.1089/brain.2020.0947

Hackney ME, Bay AA, Jackson JM, Nocera J, Krishnamurthy V, Evatt ML, Langley J, Cui X, McKay JL, Huddleston DE. Rationale and Design of the PAIRED Trial: Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease. *Front Neurol.* (2020) Oct 9;11:943. doi:10.3389/fneur.2020.00943

Langley J, Huddleston DE, Crosson B, Song DD, Factor SA, Hu X. Multimodal assessment of nigrosomal degeneration in Parkinson's disease. *Parkinsonism & Related Disorders*. (2020) Sep;80:102-107. doi: 10.1016/j.parkreldis.2020.09.021

He N, Langley J, Huddleston DE, Chen S, Huang P, Ling H, Yan F, Hu X. Increased iron-deposition in lateral-ventral substantia nigra pars-compacta: A promising neuroimaging marker for Parkinson's disease. *NeuroImage: Clinical*. (2020) Aug; 28. doi: 10.1016/j.nicl.2020/102391

Fischer NM, Hinkle JT, Perepezko K, Bakker CC, Morris M, Broen MPG, Butala A, Dawson TM, Leentjens AFG, Mari Z, Marvel CL, Mills KA, Rosenthal LS, Shepard MD, Pantelyat A, Bakker A, Pletnikova O, Troncoso JC, Wang J, Pontone GM. Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. *Am J Geriatr Psychiatry*. 2021 Jan 14:S1064-7481(20)30577-7.

Paez AG, Gu C, Rajan S, Miao X, Cao D, Kamath V, Bakker A, Unschuld PG, Pantelyat AY, Rosenthal LS, Hua J. Differential Changes in Arteriolar Cerebral Blood Volume between Parkinson's Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorder - An Exploratory Study. *Tomography*. 2020 Dec;6(4):333-342.

Ye R, Locascio JJ, Goodheart AE, Quan M, Zhang B, Gomperts SN. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study. *Parkinsonism Relat Disord*. 2021 Apr;85:11-16. doi: 10.1016/j.parkreldis.2021.02.008. Epub 2021 Feb 17. PMID: 33639572

Huh YE, Chiang MSR, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Sardi SP, Scherzer CR.  $\beta$ -Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. *Neurology*. 2020 Aug 11;95(6):e685-e696. doi: 10.1212/WNL.0000000000009989. Epub 2020 Jun 15. PMID: 32540937

Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. *J Parkinsons Dis*. 2020;10(2):505-510. doi: 10.3233/JPD-191882. PMID: 32250320

Kamil RJ, Bakar D, Ehrenburg M, Wei EX, Pletnikova A, Xiao G, Oh ES, Mancini M, Agrawal Y. Detection of Wandering Behaviors Using a Body-Worn Inertial Sensor in Patients With Cognitive Impairment: A Feasibility Study. *Front Neurol*. 2021 Mar 11;12:529661. doi: 10.3389/fneur.2021.529661. eCollection 2021. PMID: 33776875

Hong Z, Tian C, Stewart T, Aro P, Soltys D, Bercow M, Sheng L, Borden K, Khrisat T, Pan C, Zabetian CP, Peskind ER, Quinn JF, Montine TJ, Aasly J, Shi M, Zhang J. Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying  $\alpha$ -Synuclein-Containing Extracellular Vesicles. *Neurology*. 2021 May 4;96(18):e2332-e2345.

Scott GD, Lim MM, Drake MG, Woltjer R, Quinn JF. Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans. *Mov Disord*. 2021 May 3. doi: 10.1002/mds.28636. Online ahead of print.

Patel RA, Joyce J, Witek N, Afshari M. GAD65 antibody-associated neurologic disease presenting with hemiparkinsonism at onset. *Neurology Clinical Practice*. published online October 19, 2020.

Bailey M, Anderson S, Hall DA. Parkinson's Disease in African Americans: A Review of the Current Literature. *J Parkinsons Dis*. 2020;10(3):831-841. doi: 10.3233/JPD-191823. PMID: 32417794; PMCID: PMC7458499.

Radder DLM, Nonnekes J, van Nimwegen M, Eggers C, Abbruzzese G, Alves G, Browner N, Chaudhuri KR, Ebersbach G, Ferreira JJ, Fleisher JE, et al. Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson's Disease. *J Parkinsons Dis*. 2020;10(3):1087-1098. doi: 10.3233/JPD-202078. PMID: 32444563; PMCID: PMC7415700.

Feeney M, Evers C, Agpalo D, Cone L, Fleisher J, et al. Utilizing patient advocates in Parkinson's disease: A proposed framework for patient engagement and the modern metrics that can determine its success. *Health Expect*. 2020 Aug;23(4):722-730. doi: 10.1111/hex.13064. Epub 2020 May 3. Erratum in: *Health Expect*. 2020 Aug;23(4):976. PMID: 32363785; PMCID: PMC7495075.

Cone L, Feeney M, Evers C, Agpalo D, Fleisher J, et al. Partnering to power progress towards a paradigm shift: Response to Riggare et al. *Health Expect*. 2020 Aug;23(4):974-975. doi: 10.1111/hex.13126. PMID: 32939945; PMCID: PMC7495060.

Fleisher JE, Sennott BJ, Myrick E, Niemet CJ, Lee M, Whitelock CM, Sanghvi M, Liu Y, Ouyang B, Hall DA, Comella CL, Chodosh J. KICK OUT PD: Feasibility and quality of life in the pilot karate intervention to change kinematic outcomes in Parkinson's Disease. *PLoS One*. 2020 Sep 9;15(9):e0237777. doi: 10.1371/journal.pone.0237777. PMID: 32903267; PMCID: PMC7480843

Sennott B, Woo K, Hess S, Mitchem D, Klostermann EC, Myrick E, Savica R, Fleisher JE. Novel Outreach Program and Practical Strategies for Patients with Parkinsonism in the COVID-19 Pandemic. *J Parkinsons Dis*. 2020;10(4):1383-1388. doi: 10.3233/JPD-202156. PMID: 32804103; PMCID: PMC7606485.

O Keefe JA, Guan J, Robertson E, Biskis A, Joyce J, Ouyang B, Liu Y, Carnes D, Purcell N, Berry-Kravis E, Hall DA. The Effects of Dual Task Cognitive Interference and Fast-Paced Walking on Gait, Turns, and Falls in Men and Women with FXTAS. *Cerebellum*. 2020;doi:10.1007/s12311-020-01199-3 PMID: None

Rafferty M, Nettnin E, MacDonald J, Goldman JG. Frameworks for Parkinson's Disease Rehabilitation Addressing When, What, and How. *Current Neurology and Neuroscience Reports* 2021; 21(3): 12. PMID: 33615420.

Goldman JG, Guerra CM. Movement Disorders and SSRIs. *Movement Disorders in Psychiatry*. Ed. Furr et al. book published in 2021.

Goldman JG. *Principles and Practice of Movement Disorders, 3<sup>rd</sup> Edition*. Ed. Fahn, Jankovic, Hallett, book published July 2021.

Shawen N, O'Brien MK, Venkatesan S, Lonini L, Simuni T, Hamilton JL, Ghaffari R, Rogers JA, Jayaraman A. Role of data measurement characteristics in the accurate detection of Parkinson's disease symptoms using wearable sensors. *J Neuroeng Rehabil*. 2020;17(1):52. Published 2020 Apr 20. doi:10.1186/s12984-020-00684-4

Pascual-Valdunciel A, Hoo G, Avrillon S, Barroso FO, Goldman JG, Hernandez-Pavon JC, Pons JL. Peripheral electrical stimulation to reduce pathological tremor: a review, *J Neuroeng Rehabil*. 2021 Feb 15;18(1):33. doi: 10.1186/s12984-021-00811-9. PMID: 33588841; PMCID: PMC7885254.

Rafferty MR, Stoff L, Palmentera P, Capraro P, Stanley I, Heinemann A, Johnson K. Employment Resources for People with Parkinson's Disease: A Resource Review and Needs Assessment. *J Occup Rehabil*. 2021 Jun;31(2):275-284. doi: 10.1007/s10926-020-09915-w. PMID: 33025272

Zeldenrust FMJ, Lidstone SC, Wu SS, Okun MS, Cubillos F, Beck JC, Davis TL, Lyons KE, Nelson EC, Rafferty MR, Schmidt PN, Marras C. Variations in hospitalization rates across Parkinson's Foundation Centers of Excellence. *Parkinsonism Relat Disord*. 2020 Dec;81:123-128. doi: 10.1016/j.parkreldis.2020.09.006. Epub 2020 Oct 3. PMID: 33120073.

Kern F, Fehlmann T, Violich I, Alsop E, Hutchins E, Kahraman M, Grammes NL, Guimaraes P, Backes C, Poston KL, Casesy B, Balling R, Geffers L, Kruger R, Galasko D, Mollenhauer B, Meese E, Wyss-Coray T, Craig DW, Keuren-Jensen KV, Keller A. Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson's disease progression. *Nature Aging* 2021 1(3):309–322.

Muller-Oehring E, Fama R, Levine TF, Hardcastle C, Prabhakar V, Goodcase R, Martin T, Bronte-Stewart HM, Poston KL<sup>o</sup>, Sullivan EV, Schulte T. Cognitive and Motor Deficits

in Older Adults with HIV Infection: Comparison with Normal Aging and Parkinson's Disease. *Journal of Neuropsychology* 2021 Jun;15(2):253-273.

Mormino E, Toueg T, Azevedo C, Castillo J, Guo W, Nadiadwala A, Corso N, Hall J, Fan A, Trelle A, Harrison M, Hunt M, Sha S, Deutsch G, James M, Fredericks C, Koran ME, Zeineh M, Poston KL<sup>o</sup>, Greicius MD, Khalighi M, Davidzon GA, Shen B,

Zaharchuck G, Wagner AD, Chin FT. Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. *European Journal of Nuclear Medicine and Molecular Imaging* 2021 Jul;48(7):2233-2244.

Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hognl B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, Kiebertz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, Simuni T, Iranzo A. Dopamine transporter imaging predicts clinically-defined  $\alpha$ -synucleinopathy in REM sleep behavior disorder. *Ann Clin Transl Neurol.* 2021 Jan;8(1):201-212. doi: 10.1002/acn3.51269. Epub 2020 Dec 15. PMID: 33321002

Berliner JM, Kluger BM, Corcos DM, Pelak VS, Gisbert R, McRae C, Atkinson CC, Schenkman M. Patient perceptions of visual, vestibular, and oculomotor deficits in people with Parkinson's disease. *Physiother Theory Pract.* 2020;36(6):701-708.

Mejia-Vergara AJ, Restrepo-Jimenez P, Pelak VS. Optical coherence tomography in mild cognitive impairment: A systematic review and meta-analysis. *Front Neurol.* 2020;11(1231). doi: 10.3389/fneur.2020.578698

Medina LD, Heffernan K, Holden SK, Simpson A, Bettcher BM. Neural correlates of daily function: a pilot study of the white matter retrogenesis hypothesis and three separate performance-based functional assessments. *Neuropsychology.* 2021 Jan;35(1):103-110.

Galvin JE, Cohen I, Greenfield KK, Walker M. The frontal behavioral battery: A measure of frontal lobe symptoms in brain aging and neurodegenerative disease. *J Alzheimers Dis.* 2021;83(2):721-739. doi: 10.3233/JAD-210446.

Tolea MI, Heo J, Chrisphonte S, Galvin JE. A Modified CAIDE Risk Score as a Screening Tool for Cognitive Impairment in Older Adults. *J Alzheimer Dis,* 2021 Jul 1. doi: 10.3233/JAD-210269.

Galvin JE, Tolea MI, Chrisphonte S. The Cognitive & Leisure Activity Scale (CLAS): A New Measure to Quantify Cognitive Activities in Older Adults with and without Cognitive Impairment. *Alzheimer Dementia* 7:e12134; 2021 (PMCID:8012243).

Ghoraani B, Galvin JE, Jimenez-Shahed J. Point of View: Wearable Systems for At-Home Monitoring in Parkinson's Disease Should Offer Clinically Actionable Information. *Parkinson Rel Disord* 84:35-39; 2021

Innis AD, Tolea MI, Galvin JE. The effect of baseline patient and caregiver mindfulness on dementia outcomes *J Alzheimers Dis* 79:1345-1367, 2021

Galvin JE, Tolea MI, Moore C, Chrisphonte S. The Number Symbol Coding Task: A Brief Measure of Executive Function to Detect Dementia and Cognitive Impairment. *PLoS One* 15:e0242233; 2020 (PMCID: 7703969)

Galvin JE, Tolea MI, Chrisphonte S. The positive and negative appraisals of caregiving (PANAC) scale: A new measure to examine the caregiving experience in Alzheimer's disease and related dementias. *Alzheimer Dementia TRCI* 6:e12104; 2020. (PMCID: 7683961)

Galvin JE, Tolea MI, Rosenfeld A, Chrisphonte S. The Quick Physical Activity Rating (QPAR) Scale: A Brief, Valid, and Reliable Assessment of Physical Activity in Older Adults With and Without Cognitive Impairment. *PLoS One* 15(10):e0241641;2020 (PMCID:7598491)

Rane S, Owen J, Hippe DS, Cholerton B, Zabetian CP, Montine TJ, Grabowski TJ (2020). White matter lesions in mild cognitive impairment and idiopathic Parkinson's disease: multimodal advanced MRI and cognitive associations. *J Neuroimaging* 30:843-850

Martini DN, Morris R, Kelly VE, Hiller A, Chung KA, Hu SC, Zabetian CP, Oakley J, Poston K, Mata I, Edwards KL, Lapidus JA, Grabowski TJ, Montine TJ, Quinn J, Horak F (2020). Sensorimotor inhibition and mobility in genetic subgroups of Parkinson's disease. *Front Neurol* (doi: 10.3389/fneur.2020.00893) (PMC7498564)

Lorenzo-Betancor O, Lin YH, Samii A, Jayadev S, Kim HM, Longfellow K, Yearout D, Mata IF, Zabetian CP (2020). Novel compound heterozygous FBXO7 mutations in a family with early onset Parkinson's disease. *Parkinsonism Relat Disord* 80:142-147 (PMC8110511)

Sarihan EI, Pérez-Palma E, Niestroj LM, Loesch D, Inca-Martinez M, Horimoto A, Cornejo-Olivas M, Torres L, Mazzetti P, Cosentino C, Sarapura-Castro E, Rivera-Valdivia A, Dieguez E, Raggio V, Lescano A, Tumas V, Borges V, Ferraz HB, Rieder CR, Schumacher-Schuh AF, Santos-Lobato BL, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Moreno S, Chana-Cuevas P, Fernandez W, Arboleda G, Arboleda H, Arboleda-Bustos CE, Yearout D, Zabetian CP, Thornton TA, O'Connor TD, Lal D, Mata IF (2021). Genome-wide analysis of copy number variation in Latin American Parkinson's disease patients. *Mov Disord* 36:434-441 (PMC8059262)



Martini DN, Morris R, Madhyastha TM, Grabowski TJ, Oakley J, Hu SC, Zabetian CP, Edwards KL, Hiller A, Chung KA, Ramsey K, Lapidus JA, Cholerton B, Montine TJ, Quinn JF, Horak FB (2021). Relationships between sensorimotor inhibition and mobility in older adults with and without Parkinson's disease. *J Gerontol A Biol Sci Med Sci* 76:630-637 (PMC8240993)

Palmer WC, Cholerton BA, Zabetian CP, Montine TJ, Grabowski TJ, Rane S. Resting-state cerebello-cortical dysfunction in Parkinson's disease. *Front Neurol* doi: 10.3389/fneur.2020.594213 (PMC7876057)

Lai D, Alipanahi B, Fontanillas P, Schwantes-An TH, Aasly J, Alcalay RN, Beecham GW, Berg D, Bressman S, Brice A, Brockman K, Clark L, Das S, Van Deerlin V, Farrer M, Trinh J, Gasser T, Goldwurm S, Emil Gustavsson, Klein C, Lang AE, Langston JW, Latourelle J, Lynch T, Marder K, Marras C, Martin ER, McLean CY, Mejia-Santana H, Molho E, Myers RH, Nuytemans L, Ozelius L, Payami H, Raymond D, Rogaeva E, Rogers MP, Ross OA, Samii A, Saunders-Pullman R, Schüle B, Schulte C, Scott WK, Tanner C, Tolosa E, Vilas D, Trojanowski JQ, Uitti R, Vance JM, Visanji NP, Wszolek ZK, Zabetian CP, Mirelman A, Giladi N, Orr-Urtreger A, Cannon P, Fiske B, Foroud T. Genome-wide association studies of LRRK2 modifiers of Parkinson's disease. *Ann Neurol* 90:76-88 (PMC8252519)

Loesch DP, Horimoto ARVR, Heilbron K, Sarihan EI, Inca-Martinez M, Mason E, Cornejo-Olivas M, Torres L, Mazzetti P, Cosentino C, Sarapura-Castro E, Rivera-Valdivia A, Medina AC, Dieguez E, Raggio V, Lescano A, Tumas V, Borges V, Ferraz HB, Rieder CR, Schumacher-Schuh A, Santos-Lobato BL, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Moreno S, Chana-Cuevas P, Fernandez W, Arboleda G, Arboleda H, Arboleda-Bustos CE, Yearout D, Zabetian CP; 23andMe Research Team, Cannon P, Thornton TA, O'Connor TD, Mata IF; Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD). Characterizing the genetic architecture of Parkinson's disease in Latinos. *Ann Neurol* Epub July 6, 2021 (doi: 10.1002/ana.26153)

Liu X, Moussa C. Regulatory Role of Ubiquitin Specific Protease-13 (USP13) in Misfolded Protein Clearance in Neurodegenerative Diseases. *Neuroscience*. 2021 Apr 15;460:161-166. doi: 10.1016/j.neuroscience.2021.02.004. Epub 2021 Feb 10. PMID: 33577955.

Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, Matar S, Ahn J, Moussa C. Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease. *Mov Disord*. 2021 Mar;36(3):740-749. doi: 10.1002/mds.28389. Epub 2020 Nov 20. PMID: 33215762; PMCID: PMC8048914.

Moussa C. Reply to "Cardiovascular Safety of Nilotinib in Alzheimer's Disease". *Ann Neurol*. 2021 Jan;89(1):196-197. doi: 10.1002/ana.25946. Epub 2020 Nov 6. PMID: 33103265.

Reifegerste J, Estabrooke IV, Russell LE, Veríssimo J, Johari K, Wilmarth B, Pagan FL, Moussa C, Ullman MT. Can sex influence the neurocognition of language? Evidence from Parkinson's disease. *Neuropsychologia*. 2020 Nov;148:107633. doi: 10.1016/j.neuropsychologia.2020.107633. Epub 2020 Sep 22. PMID: 32971096; PMCID: PMC8613481.

Fowler AJ, Hebron M, Balaraman K, Shi W, Missner AA, Greenzaid JD, Chiu TL, Ullman C, Weatherdon E, Duka V, Torres-Yaghi Y, Pagan FL, Liu X, Resson H, Ahn J, Wolf C, Moussa C. Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases. *Hum Mol Genet*. 2020 Oct 10;29(17):2882-2898. doi: 10.1093/hmg/ddaa177. Erratum in: *Hum Mol Genet*. 2021 Jun 17;30(13):1271-1272. PMID: 32776088; PMCID: PMC7566445.

Moussa C. Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease-Reply. *JAMA Neurol*. 2020 Aug 1;77(8):1039-1040. doi: 10.1001/jamaneurol.2020.1931. PMID: 32597985.

Fowler AJ, Hebron M, Balaraman K, Shi W, Missner AA, Greenzaid JD, Chiu TL, Ullman C, Weatherdon E, Duka V, Torres-Yaghi Y, Pagan FL, Liu X, Resson H, Ahn J, Wolf C, Moussa C. Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases. *Hum Mol Genet*. 2021 Jun 17;30(13):1271-1272. doi: 10.1093/hmg/ddab082. Erratum for: *Hum Mol Genet*. 2020 Oct 10;29(17):2882-2898. PMID: 34028526; PMCID: PMC8212769.